Replimune Group 3Q 2026: Revenue $0 Net loss $57.1M, EPS ($0.54) — 10-Q Summary
Replimune Group reported no revenue in Q3 2026, with net loss narrowing to $57.1M from $83.1M a year earlier. Diluted loss per share was $0.54. The FDA approved TUDRIQEV in August, with U.S. sales starting in October. Over 15 institutions began treatments by October 23. The company is conducting clinical trials for TUDRIQEV and RP2.
How this was made
The 30-second read
Why it matters
Traders can update expectations for commercialization timing (revenue lag after FDA accelerated approval) and monitor upcoming confirmatory and RP2 REVEAL milestones that could affect risk perception.
Market read
The filing provides a concrete post-approval commercialization timeline (availability in early October) alongside financials showing no product revenue yet, informing near-term valuation and catalyst tracking.
What to watch
Confirmatory IGNYTE-3 enrollment of about 400 patients and the planned Phase 2/3 transition for RP2 REVEAL in 1Q 2027 may be the next major inflection points, not the current quarter’s revenue.
Background
The article summarizes Replimune Group’s 3Q 2026 10-Q, including financial results and commercialization/clinical trial status for TUDRIQEV.
Ticker impact
Replimune Group reported 3Q 2026 revenue of $0, net loss of $57.1M, and noted TUDRIQEV commercial sales began in October after FDA accelerated approval.
Likely mixed reaction, with downside from $0 revenue and cash-burn optics offset by upside from FDA approval and early uptake signals.
The filing provides both financial drag (no product revenue, large net loss) and a key regulatory/commercial milestone (accelerated approval in August, availability in early October, institutions treating patients).
Market effects
Highlights the commercialization ramp risk for oncology biotechs post-accelerated approval, where revenue may lag approval by quarters.
None material beyond US biotech investor sentiment.
Limited, focused on a single US-listed biotech and its US regulatory/commercial timeline.
Counterpoint
Early payer coverage and institution treatment counts may not translate into meaningful revenue quickly, so the $0 revenue quarter could dominate valuation.
Key entities
- companyReplimune Group, Inc.
US-listed biotech whose 3Q 2026 10-Q is summarized, including $0 product revenue and FDA accelerated approval for TUDRIQEV.
- productTUDRIQEV
Oncology therapy that received FDA accelerated approval in August 2026 and began US commercial availability in early October.
- clinical_trialIGNYTE-3
Confirmatory trial enrolling about 400 patients, with continued enrollment referenced in the filing summary.
- clinical_trialRP2 REVEAL
Phase 2/3 transition expected in first quarter of 2027, with preliminary findings in liver and biliary cancers expected then.
